| 1.76 0.08 (4.76%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.19 | 1-year : | 2.36 |
| Resists | First : | 1.87 | Second : | 2.02 |
| Pivot price | 1.81 |
|||
| Supports | First : | 1.64 | Second : | 1.37 |
| MAs | MA(5) : | 1.71 |
MA(20) : | 1.81 |
| MA(100) : | 2.02 |
MA(250) : | 1.86 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.1 |
D(3) : | 13.8 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 3.44 | Low : | 0.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BYSI ] has closed above bottom band by 35.2%. Bollinger Bands are 46.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.76 - 1.77 | 1.77 - 1.78 |
| Low: | 1.63 - 1.64 | 1.64 - 1.65 |
| Close: | 1.74 - 1.76 | 1.76 - 1.78 |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Wed, 24 Sep 2025
Decheng Capital funds sell $20,752 in BeyondSpring (BYSI) shares By Investing.com - Investing.com Nigeria
Wed, 24 Sep 2025
BeyondSpring (NASDAQ:BYSI) Stock Price Down 7.3% - Should You Sell? - MarketBeat
Tue, 16 Sep 2025
Decheng capital funds sell $7.6k in BeyondSpring (BYSI) shares - Investing.com
Thu, 11 Sep 2025
Decheng capital funds sell $40k in BeyondSpring (BYSI) shares - Investing.com
Wed, 13 Aug 2025
Cancer Drug Breakthrough: BeyondSpring's Plinabulin Revives Immune Response in Treatment-Resistant Patients - Stock Titan
Tue, 10 Jun 2025
Here's Why BeyondSpring (NASDAQ:BYSI) Must Use Its Cash Wisely - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 15.2 (%) |
| Held by Institutions | 14.5 (%) |
| Shares Short | 2,130 (K) |
| Shares Short P.Month | 2,160 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -8.81 |
| PEG Ratio | 0 |
| Price to Book value | -2.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|